Proteomic landscape of Alzheimer's Disease: novel insights into pathogenesis and biomarker discovery
Mass spectrometry-based proteomics empowers deep profiling of proteome and protein
posttranslational modifications (PTMs) in Alzheimer's disease (AD). Here we review the …
posttranslational modifications (PTMs) in Alzheimer's disease (AD). Here we review the …
Complement in the brain: contributions to neuroprotection, neuronal plasticity, and neuroinflammation
SS Bohlson, AJ Tenner - Annual Review of Immunology, 2023 - annualreviews.org
The complement system is an ancient collection of proteolytic cascades with well-described
roles in regulation of innate and adaptive immunity. With the convergence of a revolution in …
roles in regulation of innate and adaptive immunity. With the convergence of a revolution in …
Cerebrospinal fluid proteomics define the natural history of autosomal dominant Alzheimer's disease
Alzheimer's disease (AD) pathology develops many years before the onset of cognitive
symptoms. Two pathological processes—aggregation of the amyloid-β (Aβ) peptide into …
symptoms. Two pathological processes—aggregation of the amyloid-β (Aβ) peptide into …
[HTML][HTML] Integrated multimodal cell atlas of Alzheimer's disease
MI Gabitto, KJ Travaglini, VM Rachleff, ES Kaplan… - Nature …, 2024 - nature.com
Alzheimer's disease (AD) is the leading cause of dementia in older adults. Although AD
progression is characterized by stereotyped accumulation of proteinopathies, the affected …
progression is characterized by stereotyped accumulation of proteinopathies, the affected …
Cerebrospinal fluid proteomics in patients with Alzheimer's disease reveals five molecular subtypes with distinct genetic risk profiles
BM Tijms, EM Vromen, O Mjaavatten, H Holstege… - Nature aging, 2024 - nature.com
Alzheimer's disease (AD) is heterogenous at the molecular level. Understanding this
heterogeneity is critical for AD drug development. Here we define AD molecular subtypes …
heterogeneity is critical for AD drug development. Here we define AD molecular subtypes …
The amyloid plaque proteome in early onset Alzheimer's disease and Down syndrome
Amyloid plaques contain many proteins in addition to beta amyloid (Aβ). Previous studies
examining plaque-associated proteins have shown these additional proteins are important; …
examining plaque-associated proteins have shown these additional proteins are important; …
A protein panel in cerebrospinal fluid for diagnostic and predictive assessment of Alzheimer's disease
Alzheimer's disease (AD) is a neurodegenerative disease with heterogenous
pathophysiological changes that develop years before the onset of clinical symptoms. These …
pathophysiological changes that develop years before the onset of clinical symptoms. These …
Omics sciences for systems biology in Alzheimer's disease: State-of-the-art of the evidence
Alzheimer's disease (AD) is characterized by non-linear, genetic-driven pathophysiological
dynamics with high heterogeneity in biological alterations and disease spatial-temporal …
dynamics with high heterogeneity in biological alterations and disease spatial-temporal …
Artificial intelligence for Alzheimer's disease: promise or challenge?
Decades of experimental and clinical research have contributed to unraveling many
mechanisms in the pathogenesis of Alzheimer's disease (AD), but the puzzle is still …
mechanisms in the pathogenesis of Alzheimer's disease (AD), but the puzzle is still …
Guidelines for bioinformatics of single-cell sequencing data analysis in Alzheimer's disease: review, recommendation, implementation and application
Alzheimer's disease (AD) is the most common form of dementia, characterized by
progressive cognitive impairment and neurodegeneration. Extensive clinical and genomic …
progressive cognitive impairment and neurodegeneration. Extensive clinical and genomic …